Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Company Drug

Eisai’s Uric Acid Excretion Drug Urece Accepted for Review in China

Fineline Cube Jan 23, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that it...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial

Fineline Cube Jan 23, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that...

Company Medical Device

Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China

Fineline Cube Jan 23, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry,...

Company Medical Device

Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device

Fineline Cube Jan 23, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease...

Company

LifeShield Medical Launches China HQ and Advanced Heart System Factory in Suzhou

Fineline Cube Jan 23, 2024

LifeShield Medical, a leading Sino-German multinational medical device company, has announced the official operation of...

Company Deals Digital Policy / Regulatory

Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative

Fineline Cube Jan 23, 2024

The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd,...

Company Deals

Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment

Fineline Cube Jan 23, 2024

Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab),...

Company Drug

HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jan 23, 2024

China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...

Policy / Regulatory

Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan

Fineline Cube Jan 23, 2024

The General Office of the CPC Central Committee and State Council has released the “Implementation...

Company Drug

AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment

Fineline Cube Jan 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...

Company Drug

Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Jan 23, 2024

Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...

Policy / Regulatory

NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions

Fineline Cube Jan 23, 2024

The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...

Company Deals

Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine

Fineline Cube Jan 23, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...

Company Deals

Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements

Fineline Cube Jan 23, 2024

Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...

Company Deals

Digital Precision Medicine Secures Over $28 Million in Series C Financing

Fineline Cube Jan 22, 2024

Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of...

Company Drug

NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin

Fineline Cube Jan 22, 2024

The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...

Company Drug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

Fineline Cube Jan 22, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...

Company Drug

AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial

Fineline Cube Jan 22, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...

Company Drug

J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment

Fineline Cube Jan 22, 2024

The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...

Policy / Regulatory

Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth

Fineline Cube Jan 22, 2024

Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...

Posts pagination

1 … 355 356 357 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.